Valrubicin(AD-32) is a chemotherapeutic agent used in the treatment of bladder cancer. Valrubicin inhibited TPA-and PDBU-induced PKC activation with IC50 values of 0.85 μM and 1.25 μM, respectively.

 

Brand: BCM

 

Target: Antibiotic; PKC

 

Signaling Pathways: Chromatin/Epigenetic; Cytoskeletal Signaling; Microbiology/Virology

 

In Vivo: Valrubicin (3, 6, or 9 mg) reduces tumor growth at week 3 by intratumoral injection in the hamster. Valrubicin (6 mg) combined with minimally cytotoxic irradiation (150, 250, or 350 cGy) causes significant tumor shrinkage in the hamster. Valrubicin (0.1 μg/μL) significantly reduces the number of infiltrating neutrophils in biopsies challenged with TPA at 24 h and attenuates chronic inflammation in mice. Valrubicin also decreases the expression levels of inflammatory cytokines in the acute model.

 

Melting Point: 116-117 °C

 

Boiling Point: 135-136°C

 

pKa: 7.34±0.60(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Ethanol. Insoluble in Water.

 

GHS: GHS06, GHS08

 

Isomeric SMILES: CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O  

 

InChIKey: ZOCKGBMQLCSHFP-KQRAQHLDSA-N  

 

InChI: InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1

 

Attribute
[Chem Name]	[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
[Synonym]	Valrubicin; AD-32
[CAS No.]	56124-62-0
[EINECS]	680-664-1
[MDL No.]	MFCD01939322
[Formula]	C34H36F3NO13
[Molecular]	723.64
[Form]	Red Solid
[Storage]	Sealed in dry, 2-8°C

Goods Tag